Study explores mGluR2 antibody approach against H9 influenza
Bottom line
A new in vitro study in Veterinary Sciences reports that monoclonal antibodies directed at metabotropic glutamate receptor 2, or mGluR2, reduced infection by H9 subtype influenza A virus in cell culture. The work builds on earlier research showing that influenza A can use mGluR2 as an endocytic receptor during cell entry, making the receptor a potential host-directed antiviral target rather than a virus-directed one. In the new study, researchers generated three anti-mGluR2 monoclonal antibodies after expressing a truncated recombinant mGluR2 fragment, then found all three bound the target strongly, with one candidate showing the most notable antiviral effect against H9 virus in vitro. (pubmed.ncbi.nlm.nih.gov)
Why it matters: For veterinary professionals, the finding is less about a near-term product and more about a possible new antiviral strategy for avian influenza research. H9 viruses circulate widely in wild and domestic birds, are endemic in poultry in parts of Asia, the Middle East, and Africa, and have recognized zoonotic relevance. Because H9N2 and related A/H9 viruses can contribute internal genes to reassortant strains and have been linked to sporadic human infections, host-targeted approaches that interfere with viral entry could eventually broaden the influenza toolbox beyond strain-specific vaccines and direct-acting antivirals. Still, this is early-stage bench science, and the current evidence is limited to cell-based experiments rather than animal studies or clinical use. (wwwnc.cdc.gov)
What to watch: The next step is whether these antibodies show activity and safety in animal models, and whether mGluR2 blockade can translate from an in vitro concept into a practical antiviral approach for poultry or broader veterinary use. (pubmed.ncbi.nlm.nih.gov)
Key facts
- Study type
- In vitro study
- Journal
- Veterinary Sciences
- Target
- Metabotropic glutamate receptor 2 (mGluR2)
- Virus
- H9 subtype influenza A virus
- Finding
- Anti-mGluR2 monoclonal antibodies reduced infection in cell culture
- Antibodies generated
- Three anti-mGluR2 monoclonal antibodies
- Lead candidate
- One candidate showed the most notable antiviral effect in vitro
- Study basis
- Built on earlier work showing influenza A can use mGluR2 as an endocytic receptor during cell entry
A newly published Veterinary Sciences study points to a host-directed way to slow H9 subtype influenza A virus infection: monoclonal antibodies aimed at mGluR2, a host-cell receptor involved in viral entry. The paper describes the generation of three anti-mGluR2 monoclonal antibodies and reports that they inhibited H9 influenza infection in vitro, with one clone emerging as the lead candidate in the experiments summarized by the journal abstract. (pubmed.ncbi.nlm.nih.gov)
The study builds on a 2024 paper in Nature Microbiology that identified mGluR2 as an endocytic receptor used by influenza A virus to initiate clathrin-mediated endocytosis. In that earlier work, influenza hemagglutinin directly interacted with mGluR2, and mGluR2-knockout mice were significantly more resistant to multiple influenza subtypes than wild-type controls. That matters because it shifts attention from targeting viral proteins alone to blocking a host pathway the virus depends on for entry. (pubmed.ncbi.nlm.nih.gov)
According to the source article summary, the authors expressed and purified a recombinant truncated mGluR2 fragment in HEK293F cells, immunized BALB/c mice, and generated three stable hybridoma clones: 1G3B2, 2D5A9, and 4E1C6. All three monoclonal antibodies showed strong binding affinity to mGluR2, and at least one demonstrated measurable inhibition of H9 influenza A virus infection in vitro. Based on the available abstract material, the study should be read as proof-of-concept work showing that interrupting the HA-mGluR2 interaction may be feasible, not as evidence of a field-ready biologic. (pubmed.ncbi.nlm.nih.gov)
The broader disease context gives the paper more relevance than its narrow laboratory scope might suggest. A/H9 viruses circulate globally in wild and domestic birds, and an international consortium recently proposed a formal nomenclature system for the subtype after documenting its ongoing evolution and spread. That review noted that A/H9N2 is endemic in poultry populations in several regions, can cause substantial economic losses through reduced egg production and increased mortality associated with coinfections, and has contributed internal genes to reassortant viruses implicated in human infections, including H3N8, H5N6, H7N9, and H10N8. (wwwnc.cdc.gov)
Public health agencies also continue to treat H9 as a zoonotic concern, even if the immediate human risk remains limited. CDC states that sporadic human infections with A(H9N2) have been reported, while WHO notes that zoonotic influenza viruses can cause illness ranging from mild disease to severe outcomes and that animal surveillance remains essential. In other words, a study focused on blocking H9 entry in vitro has implications beyond poultry virology alone. (cdc.gov)
Expert reaction specific to this paper was limited in public sources, but the surrounding influenza literature supports the strategic rationale. Host-directed antiviral reviews and prior influenza antibody programs suggest the appeal of approaches that may be less vulnerable to rapid antigenic drift than strain-matched interventions. At the same time, host targeting brings its own questions, especially around tissue distribution, off-target effects, dosing practicality, and whether interference with a host receptor can be done safely enough for real-world veterinary use. That caution is an inference from the mechanism and stage of development, rather than a direct claim from the paper. (mdpi.com)
Why it matters: For veterinarians and animal health watchers, this is an early signal in the larger shift toward host-directed influenza countermeasures. If mGluR2 blockade proves effective beyond cell culture, it could eventually complement vaccination and biosecurity by offering a subtype-relevant antiviral approach that does not rely solely on chasing viral mutations. That could be especially valuable in settings where H9 viruses are entrenched in poultry populations or where reassortment risk keeps pressure on surveillance systems. But the translational gap is still wide: there is no evidence yet here for efficacy in live birds, companion animals, livestock species, or pet parents’ households. (wwwnc.cdc.gov)
What to watch: The key milestones will be full publication details on potency and mechanism, followed by animal-model validation, safety studies, and any signs that anti-mGluR2 antibodies can be developed into a practical preventive or therapeutic platform rather than remaining a useful laboratory insight. (pubmed.ncbi.nlm.nih.gov)